share_log

Intelligent Bio Solutions | UPLOAD: Others

Intelligent Bio Solutions | UPLOAD: Others

Intelligent Bio Solutions | UPLOAD:其他
美股sec公告 ·  03/25 22:15
Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 18, 2024, will not undergo review by the commission. The SEC's communication, dated March 22, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions Inc. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Juan Grana, a contact person at the SEC, was mentioned for any further inquiries.
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 18, 2024, will not undergo review by the commission. The SEC's communication, dated March 22, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions Inc. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Juan Grana, a contact person at the SEC, was mentioned for any further inquiries.
美國證券交易委員會(SEC)已通知在美國上市的Intelligent Bio Solutions Inc.,其於2024年3月18日提交的S-3表格註冊聲明將不接受該委員會的審查。美國證券交易委員會的信函於2024年3月22日發給了智能生物解決方案公司首席執行官哈里·西蒙尼迪斯。美國證券交易委員會的信提醒該公司及其管理層,無論美國證券交易委員會的審查程序如何,他們都對披露的準確性和充分性負責。美國證券交易委員會還引用了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會聯繫人胡安·格拉納被提及需要進一步調查。
美國證券交易委員會(SEC)已通知在美國上市的Intelligent Bio Solutions Inc.,其於2024年3月18日提交的S-3表格註冊聲明將不接受該委員會的審查。美國證券交易委員會的信函於2024年3月22日發給了智能生物解決方案公司首席執行官哈里·西蒙尼迪斯。美國證券交易委員會的信提醒該公司及其管理層,無論美國證券交易委員會的審查程序如何,他們都對披露的準確性和充分性負責。美國證券交易委員會還引用了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會聯繫人胡安·格拉納被提及需要進一步調查。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息